
    
      Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer
      patients.

        -  Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA
           extracted from collected patient samples.

        -  Correlation analysis of KRAS mutation results with clinical data.

      Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

        -  Gene panel composition for pancreatic cancer therapeutic target determination and
           monitoring.

        -  A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic
           cancer patients.

        -  Comparative analysis of panel results and quantitative KRAS mutations and evaluation of
           clinical applicability.
    
  